High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma

被引：2

作者：

Altundag, K ^{[1
]}

Altundag, O

Morandi, P

Gunduz, M

机构：

[1] Hacettepe Univ, Fac Med, Dept Med Oncol, Ankara, Turkey

[2] San Bortolo Gen Hosp, Dept Med Oncol, Vicenza, Italy

[3] Okayama Univ, Grad Sch Med & Dent, Dept Otolaryngol, Okayama, Japan

来源：

CANCER | 2004年 / 101卷 / 05期

关键词：

D O I：

10.1002/cncr.20459

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1101 / 1102

页数：2

共 6 条

[1] Osteoprotegerin and its cognate ligand: a new paradigm of osteoclastogenesis [J].

Hofbauer, LC ;

Heufelder, AE .

EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1998, 139 (02) :152-154

[2] High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma [J].

Morris, MJ ;

Smaletz, O ;

Solit, D ;

Kelly, WK ;

Slovin, S ;

Flombaum, C ;

Curley, T ;

Delacruz, A ;

Schwartz, L ;

Fleisher, M ;

Zhu, Z ;

Diani, M ;

Fallon, M ;

Scher, HI .

CANCER, 2004, 100 (09) :1868-1875

[3] Mechanisms of disease: Mechanisms of bone metastasis [J].

Roodman, GD .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (16) :1655-1664

[4]

Ross J R, 2004, Health Technol Assess, V8, P1

[5] A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma [J].

Saad, F ;

Gleason, DM ;

Murray, R ;

Tchekmedyian, S ;

Venner, P ;

Lacombe, L ;

Chin, JL ;

Vinholes, JJ ;

Goas, JA ;

Chen, B .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (19) :1458-1468

[6] Osteoclast differentiation factor is a ligand for osteoprotegerin osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL [J].

Yasuda, H ;

Shima, N ;

Nakagawa, N ;

Yamaguchi, K ;

Kinosaki, M ;

Mochizuki, S ;

Tomoyasu, A ;

Yano, K ;

Goto, M ;

Murakami, A ;

Tsuda, E ;

Morinaga, T ;

Higashio, K ;

Udagawa, N ;

Takahashi, N ;

Suda, T .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (07) :3597-3602

← 1 →